Centrally Authorised Products (CAPs) Bridging Mechanism
This guidance applies until such time as the Windsor Framework takes effect on 1 January 2025. Under the Windsor Framework, rather than novel medicines for use in Northern Ireland requiring…
Chapter 5 – presentation guidance – Great Britain
Information on naming, presentation and packaging when submitting a notification of intent to market e-cigarette and vape products in Great Britain.
Converting Parallel Distribution Notices (PDNs) to UK Parallel Import Licences (PILs)
Converting Parallel Distribution Notices (PDNs) to UK Parallel Import Licences (PILs)The UK has in place arrangements for the continued authorisation of medicinal products.Great BritainParallel Distribution Notices are no longer valid…
Squamous cell carcinoma (SCC) and different types of lymphomas occurring in the capsule around breast implants
The Medicines and Healthcare products Regulatory Agency (MHRA) are continuing to closely monitor for cases of SCC and other types of lymphoma and the published literature.
Repeal of wholesale dealer licence exemption for pharmacists
The exemption enabling pharmacists to trade medicines in certain circumstances without a WDA(H) was repealed in 2012. This guidance covers the implications when supplying licensed medicines other than directly to…
